VTP 200
Alternative Names: ChadOx1-HPV; VTP-200Latest Information Update: 23 Apr 2024
Price :
$50 *
At a glance
- Originator University of Oxford
- Developer Barinthus Biotherapeutics
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Human papillomavirus infections
Most Recent Events
- 18 Apr 2024 Updated immunogenicity and adverse events data from the phase I/II APOLLO trial in Human papillomavirus infections released by Barinthus Bio
- 16 Jan 2024 Barinthus biotherapeutics completes the phase-I/II trial in Human papillomavirus infections (Prevention) in Belgium, Estonia, and UK (IM) (NCT04607850)
- 17 Apr 2023 Vaccitech completes enrolment in its phase Ib/II APOLLO trial for cervical lesions in UK and Belgium (NCT04607850)